20/02/2026
Webinar Highlight From StressMarq Biosciences Inc.: Advancing the Frontiers of Parkinson’s Research
Parkinson’s disease is one of the most complex neurodegenerative disorders to diagnose early. Traditional diagnostics often miss the earliest molecular signals and can’t reliably differentiate PD from other synucleinopathies such as dementia with Lewy bodies (DLB) or multiple system atrophy (MSA). In this webinar, experts explain how alpha synuclein seed amplification assays (SAAs), particularly RT-QuIC, are redefining early detection by identifying trace pathogenic protein seeds with high sensitivity and specificity.
Featuring Dr. Laura Parkkinen - Professor of Translational Neuropathology and Director of the Oxford Brain Bank, University of Oxford discusses foundational science, clinical relevance, and the future of SAAs in neurodegenerative research.
Key takeaways include:
• The scientific principles and workflow behind alpha-synuclein SAAs
• Current challenges around assay standardisation and reproducibility
• How advances in recombinant protein technology are helping improve assay performance for research and future diagnostics
Watch the on-demand webinar to learn more about this rapidly evolving field: https://www.youtube.com/watch?v=7snt2XKJuM8&t=1s
Parkinson’s disease (PD) remains one of the most challenging neurodegenerative disorders to diagnose and monitor. Conventional clinical assessments and imagi...